FEMYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

FEMASYS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.63−0.02 (-1.21%)

Close on Oct 19, 2026

Market cap: $5.47M
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$2.29MFY2025, +17.2% a year since FY2020

Where these numbers come from

Parsed from the XBRL in Femasys's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Jun 8, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is FEMY.

Revenue growth21.9% · median -28.5%

Gross margin60.9% · median 48.6%

Operating margin-763.9% · median -592.0%

Net margin-511.8% · median -294.9%

Company	Revenue	Growth
IVF	$7.53M	–
INBS	$4.22M	+38.1%
FEMY	$2.30M	+21.9%
OSRH	$1.81M	-50.2%
SINT	$1.33M	-28.5%
ICCM	–	–

Company

Next earnings (est.): Nov 13, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 51
Held by institutions: 24.7%
Auditor: KPMG LLP
SEC CIK: 1339005

Advertisement
300 × 250